Literature DB >> 94405

Hemodynamic consequences of long-term beta-blocker therapy: a 5-year follow-up study of atenolol.

P Lund-Johansen.   

Abstract

The long-term hemodynamic effects of atenolol were studied in 10 patients with previously untreated essential hypertension in WHO stage I. Oxygen consumption, heart rate, cardiac output, and intra-arterial brachial pressure were recorded at rest in supine and sitting positions and during steady-state work at 50, 100, and 150 W. The patients were treated with 100 mg atenolol daily (200 mg in 1 patient) as the sole antihypertensive drug and were restudied after 1 and 5 years. After 1 year the blood pressure was reduced approximately 18% both at rest and during exercise, and the heart rate about 25%. The cardiac output was reduced 16% at rest supine, 27% at rest sitting, and about 20% during exercise. The calculated total peripheral resistance was not decreased compared to pretreatment values. After 5 years on treatment, the hemodynamic parameters were almost identical to those seen after 1 year. There was no increase in stroke volume or cardiac output and no decrease in the total peripheral resistance. Thus prolonged beta-blocker treatment over several years does not seem to normalize hemodynamics in patients with mild to moderate essential hypertension.

Entities:  

Mesh:

Substances:

Year:  1979        PMID: 94405     DOI: 10.1097/00005344-197909000-00001

Source DB:  PubMed          Journal:  J Cardiovasc Pharmacol        ISSN: 0160-2446            Impact factor:   3.105


  24 in total

Review 1.  Why beta-blockers are not cardioprotective in elderly patients with hypertension.

Authors:  Ehud Grossman; Franz H Messerli
Journal:  Curr Cardiol Rep       Date:  2002-11       Impact factor: 2.931

Review 2.  The role of Beta-blockers as first-line therapy in hypertension.

Authors:  Alberto Ranieri De Caterina; Antonio Maria Leone
Journal:  Curr Atheroscler Rep       Date:  2011-04       Impact factor: 5.113

3.  Ergometry as a basis for judging the antihypertensive effect.

Authors:  I W Franz; U Tönnesmann; D Erb; R Ketelhut
Journal:  Drugs       Date:  1990       Impact factor: 9.546

4.  Effect of celiprolol therapy on arterial dilatation in experimental hypertension.

Authors:  J P Tolvanen; X Wu; M Kähönen; K Sallinen; H Mäkynen; A Pekki; I Pörsti
Journal:  Br J Pharmacol       Date:  1996-11       Impact factor: 8.739

5.  Atenolol blunts blood pressure increase during dynamic resistance exercise in hypertensives.

Authors:  Ricardo S Gomides; Luiz A R Costa; Dinoélia R Souza; Andréia C C Queiroz; João R C Fernandes; Kátia C Ortega; Décio Mion Junior; Taís Tinucci; Cláudia L M Forjaz
Journal:  Br J Clin Pharmacol       Date:  2010-11       Impact factor: 4.335

6.  Haemodynamic differences in untreated hypertension and hypertension treated with various beta-adrenoceptor antagonists.

Authors:  C Weil; R Waite
Journal:  Br J Clin Pharmacol       Date:  1982       Impact factor: 4.335

7.  A comparison of labetalol and prazosin combined with atenolol in non-responders to atenolol plus hydrochlorothiazide in uncomplicated hypertension.

Authors:  E van der Veur; B S ten Berge; A J Donker; J F May; F H Schuurman; H Wesseling
Journal:  Eur J Clin Pharmacol       Date:  1985       Impact factor: 2.953

8.  Comparison of the antihypertensive effects of carvedilol and metoprolol on resting and exercise blood pressure.

Authors:  I W Franz; B Agrawal; D Wiewel; R Ketelhut
Journal:  Clin Investig       Date:  1992

Review 9.  Heart rate control with adrenergic blockade: clinical outcomes in cardiovascular medicine.

Authors:  David Feldman; Terry S Elton; Doron M Menachemi; Randy K Wexler
Journal:  Vasc Health Risk Manag       Date:  2010-06-01

10.  Role of the Frank-Starling mechanism during maximal semisupine exercise after oral atenolol.

Authors:  K Andersen; H Vik-Mo
Journal:  Br Heart J       Date:  1982-08
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.